SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Identifieur interne : 000586 ( Main/Curation ); précédent : 000585; suivant : 000587SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Auteurs : Maddalena Giglia [Italie] ; Giacomo Beci [Italie] ; Elena Rosselli Del Turco [Oman] ; Viola Guardigni [Italie] ; Alberto Amedeo [Italie] ; Giulia Cucchetto [Italie] ; Gabriella Verucchi [Italie] ; Marco Cipolli [Italie] ; Leonardo Calza [Italie] ; Pierluigi Viale [Italie]Source :
- Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace [ 1122-0643 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Anticorps monoclonaux humanisés (administration et posologie), Antiviraux (administration et posologie), Association médicamenteuse (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Infections de l'appareil respiratoire (microbiologie), Infections de l'appareil respiratoire (traitement médicamenteux), Infections de l'appareil respiratoire (étiologie), Lopinavir (administration et posologie), Mucoviscidose (complications), Mucoviscidose (immunologie), Mucoviscidose (physiopathologie), Mâle (MeSH), Oxygénothérapie (méthodes), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (étiologie), Poumon (imagerie diagnostique), Poumon (physiopathologie), Ritonavir (administration et posologie), Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs), Résultat thérapeutique (MeSH), Tests de la fonction respiratoire (méthodes), Tomodensitométrie (méthodes).
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Antiviraux, Hydroxychloroquine, Lopinavir, Ritonavir.
- antagonistes et inhibiteurs : Récepteurs à l'interleukine-6.
- diagnostic : Pneumopathie virale.
- imagerie diagnostique : Poumon.
- immunologie : Mucoviscidose.
- microbiologie : Infections de l'appareil respiratoire.
- méthodes : Oxygénothérapie, Tests de la fonction respiratoire, Tomodensitométrie.
- physiopathologie : Mucoviscidose, Poumon.
- traitement médicamenteux : Infections de l'appareil respiratoire, Pneumopathie virale.
- étiologie : Infections de l'appareil respiratoire, Pneumopathie virale.
- complications : Adulte, Association médicamenteuse, Humains, Mucoviscidose, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adult (MeSH), Antibodies, Monoclonal, Humanized (administration & dosage), Antiviral Agents (administration & dosage), COVID-19 (complications), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (physiopathology), Cystic Fibrosis (complications), Cystic Fibrosis (immunology), Cystic Fibrosis (physiopathology), Drug Combinations (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Lopinavir (administration & dosage), Lung (diagnostic imaging), Lung (physiopathology), Male (MeSH), Oxygen Inhalation Therapy (methods), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (etiology), Receptors, Interleukin-6 (antagonists & inhibitors), Respiratory Function Tests (methods), Respiratory Tract Infections (drug therapy), Respiratory Tract Infections (etiology), Respiratory Tract Infections (microbiology), Ritonavir (administration & dosage), SARS-CoV-2 (isolation & purification), Tomography, X-Ray Computed (methods), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antiviral Agents, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemical , antagonists & inhibitors : Receptors, Interleukin-6.
- complications : COVID-19, Cystic Fibrosis.
- diagnosis : COVID-19, Pneumonia, Viral.
- diagnostic imaging : Lung.
- drug therapy : COVID-19, Pneumonia, Viral, Respiratory Tract Infections.
- etiology : Pneumonia, Viral, Respiratory Tract Infections.
- immunology : Cystic Fibrosis.
- isolation & purification : SARS-CoV-2.
- methods : Oxygen Inhalation Therapy, Respiratory Function Tests, Tomography, X-Ray Computed.
- microbiology : Respiratory Tract Infections.
- physiopathology : COVID-19, Cystic Fibrosis, Lung.
- Adult, Drug Combinations, Humans, Male, Treatment Outcome.
Abstract
We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.
DOI: 10.4081/monaldi.2020.1579
PubMed: 33372741
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000586
Links to Exploration step
pubmed:33372741Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?</title>
<author><name sortKey="Giglia, Maddalena" sort="Giglia, Maddalena" uniqKey="Giglia M" first="Maddalena" last="Giglia">Maddalena Giglia</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. maddalena.giglia@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Beci, Giacomo" sort="Beci, Giacomo" uniqKey="Beci G" first="Giacomo" last="Beci">Giacomo Beci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. giacomo.beci@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Rosselli Del Turco, Elena" sort="Rosselli Del Turco, Elena" uniqKey="Rosselli Del Turco E" first="Elena" last="Rosselli Del Turco">Elena Rosselli Del Turco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. erossellidelturco@gmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
<author><name sortKey="Guardigni, Viola" sort="Guardigni, Viola" uniqKey="Guardigni V" first="Viola" last="Guardigni">Viola Guardigni</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. viola.guardigni2@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Amedeo, Alberto" sort="Amedeo, Alberto" uniqKey="Amedeo A" first="Alberto" last="Amedeo">Alberto Amedeo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. alberto.amedeo@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Cucchetto, Giulia" sort="Cucchetto, Giulia" uniqKey="Cucchetto G" first="Giulia" last="Cucchetto">Giulia Cucchetto</name>
<affiliation wicri:level="1"><nlm:affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. giulia.cucchetto@aovr.veneto.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. gabriella.verucchi@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Cipolli, Marco" sort="Cipolli, Marco" uniqKey="Cipolli M" first="Marco" last="Cipolli">Marco Cipolli</name>
<affiliation wicri:level="1"><nlm:affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. marco.cipolli@aovr.veneto.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Calza, Leonardo" sort="Calza, Leonardo" uniqKey="Calza L" first="Leonardo" last="Calza">Leonardo Calza</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. leonardo.calza@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. pierluigi.viale@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33372741</idno>
<idno type="pmid">33372741</idno>
<idno type="doi">10.4081/monaldi.2020.1579</idno>
<idno type="wicri:Area/Main/Corpus">000586</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000586</idno>
<idno type="wicri:Area/Main/Curation">000586</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000586</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?</title>
<author><name sortKey="Giglia, Maddalena" sort="Giglia, Maddalena" uniqKey="Giglia M" first="Maddalena" last="Giglia">Maddalena Giglia</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. maddalena.giglia@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Beci, Giacomo" sort="Beci, Giacomo" uniqKey="Beci G" first="Giacomo" last="Beci">Giacomo Beci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. giacomo.beci@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Rosselli Del Turco, Elena" sort="Rosselli Del Turco, Elena" uniqKey="Rosselli Del Turco E" first="Elena" last="Rosselli Del Turco">Elena Rosselli Del Turco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. erossellidelturco@gmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
<author><name sortKey="Guardigni, Viola" sort="Guardigni, Viola" uniqKey="Guardigni V" first="Viola" last="Guardigni">Viola Guardigni</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. viola.guardigni2@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Amedeo, Alberto" sort="Amedeo, Alberto" uniqKey="Amedeo A" first="Alberto" last="Amedeo">Alberto Amedeo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. alberto.amedeo@studio.unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Cucchetto, Giulia" sort="Cucchetto, Giulia" uniqKey="Cucchetto G" first="Giulia" last="Cucchetto">Giulia Cucchetto</name>
<affiliation wicri:level="1"><nlm:affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. giulia.cucchetto@aovr.veneto.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. gabriella.verucchi@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Cipolli, Marco" sort="Cipolli, Marco" uniqKey="Cipolli M" first="Marco" last="Cipolli">Marco Cipolli</name>
<affiliation wicri:level="1"><nlm:affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. marco.cipolli@aovr.veneto.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Calza, Leonardo" sort="Calza, Leonardo" uniqKey="Calza L" first="Leonardo" last="Calza">Leonardo Calza</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. leonardo.calza@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
<author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. pierluigi.viale@unibo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
</affiliation>
</author>
</analytic>
<series><title level="j">Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</title>
<idno type="ISSN">1122-0643</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>COVID-19 (complications)</term>
<term>COVID-19 (diagnosis)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (physiopathology)</term>
<term>Cystic Fibrosis (complications)</term>
<term>Cystic Fibrosis (immunology)</term>
<term>Cystic Fibrosis (physiopathology)</term>
<term>Drug Combinations (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Lopinavir (administration & dosage)</term>
<term>Lung (diagnostic imaging)</term>
<term>Lung (physiopathology)</term>
<term>Male (MeSH)</term>
<term>Oxygen Inhalation Therapy (methods)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (etiology)</term>
<term>Receptors, Interleukin-6 (antagonists & inhibitors)</term>
<term>Respiratory Function Tests (methods)</term>
<term>Respiratory Tract Infections (drug therapy)</term>
<term>Respiratory Tract Infections (etiology)</term>
<term>Respiratory Tract Infections (microbiology)</term>
<term>Ritonavir (administration & dosage)</term>
<term>SARS-CoV-2 (isolation & purification)</term>
<term>Tomography, X-Ray Computed (methods)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Anticorps monoclonaux humanisés (administration et posologie)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Infections de l'appareil respiratoire (microbiologie)</term>
<term>Infections de l'appareil respiratoire (traitement médicamenteux)</term>
<term>Infections de l'appareil respiratoire (étiologie)</term>
<term>Lopinavir (administration et posologie)</term>
<term>Mucoviscidose (complications)</term>
<term>Mucoviscidose (immunologie)</term>
<term>Mucoviscidose (physiopathologie)</term>
<term>Mâle (MeSH)</term>
<term>Oxygénothérapie (méthodes)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (étiologie)</term>
<term>Poumon (imagerie diagnostique)</term>
<term>Poumon (physiopathologie)</term>
<term>Ritonavir (administration et posologie)</term>
<term>Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Tests de la fonction respiratoire (méthodes)</term>
<term>Tomodensitométrie (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Interleukin-6</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Antiviraux</term>
<term>Hydroxychloroquine</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs à l'interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term>
<term>Cystic Fibrosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Pneumonia, Viral</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pneumonia, Viral</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Mucoviscidose</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cystic Fibrosis</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Oxygen Inhalation Therapy</term>
<term>Respiratory Function Tests</term>
<term>Tomography, X-Ray Computed</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Oxygénothérapie</term>
<term>Tests de la fonction respiratoire</term>
<term>Tomodensitométrie</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Mucoviscidose</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term>
<term>Cystic Fibrosis</term>
<term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Drug Combinations</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="fr"><term>Adulte</term>
<term>Association médicamenteuse</term>
<term>Humains</term>
<term>Mucoviscidose</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33372741</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1122-0643</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>90</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Dec</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</Title>
<ISOAbbreviation>Monaldi Arch Chest Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.4081/monaldi.2020.1579</ELocationID>
<Abstract><AbstractText>We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giglia</LastName>
<ForeName>Maddalena</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. maddalena.giglia@studio.unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beci</LastName>
<ForeName>Giacomo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. giacomo.beci@studio.unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosselli Del Turco</LastName>
<ForeName>Elena</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. erossellidelturco@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guardigni</LastName>
<ForeName>Viola</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. viola.guardigni2@unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Amedeo</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. alberto.amedeo@studio.unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cucchetto</LastName>
<ForeName>Giulia</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. giulia.cucchetto@aovr.veneto.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Verucchi</LastName>
<ForeName>Gabriella</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. gabriella.verucchi@unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cipolli</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Cystic Fibrosis Regional Centre, AOUI Verona. marco.cipolli@aovr.veneto.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Calza</LastName>
<ForeName>Leonardo</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. leonardo.calza@unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Viale</LastName>
<ForeName>Pierluigi</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna. pierluigi.viale@unibo.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>12</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Monaldi Arch Chest Dis</MedlineTA>
<NlmUniqueID>9307314</NlmUniqueID>
<ISSNLinking>1122-0643</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>08</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>11</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>8</Hour>
<Minute>38</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33372741</ArticleId>
<ArticleId IdType="doi">10.4081/monaldi.2020.1579</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000586 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000586 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:33372741 |texte= SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:33372741" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |